Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / BARDA - Page 2

BARDA

Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19

On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…

Read More Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19Continue

BARDA procured Regeneron’s REGN-EB3 investigational Ebola treatment for national preparedness
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics | Vaccine

BARDA procured Regeneron’s REGN-EB3 investigational Ebola treatment for national preparedness

On Jul. 29, 2020, Regeneron announced that the Biomedical Advanced Research and Development Authority (BARDA) had entered into…

Read More BARDA procured Regeneron’s REGN-EB3 investigational Ebola treatment for national preparednessContinue

Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19

On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…

Read More Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19Continue

BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaigns
Biotechnology | COVID-19 | Infectious Disease | Medical Device | Vaccine

BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaigns

On Jul. 8, 2020, BD (Becton, Dickinson) announced the formation of a strategic, public-private partnership with the Biomedical…

Read More BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaignsContinue

Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail

On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and…

Read More Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktailContinue

Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidate
Biotechnology | Infectious Disease | Vaccine

Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidate

On Jun. 30, 2020, Altimmune announced dosing of the first patient in the Company’s Phase 1b clinical trial…

Read More Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidateContinue

SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million
Biotechnology | Infectious Disease | Therapeutics

SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million

On Jun. 25, 2020, SIGA Technologies announced the deliveries of oral TPOXX (tecovirimat) to the U.S. Department of…

Read More SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 millionContinue

Quidel received BARDA funding to develop point-of-care diagnostic assay that includes COVID-19
Biotechnology | Diagnostics | Infectious Disease | Influenza

Quidel received BARDA funding to develop point-of-care diagnostic assay that includes COVID-19

On Jun. 11, 2020, Quidel announced it had received funding from the Biomedical Advanced Research and Development Authority…

Read More Quidel received BARDA funding to develop point-of-care diagnostic assay that includes COVID-19Continue

OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samples
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samples

On Jun. 10, 2020, OraSure Technologies announced it had been awarded a $629,217 contract from the Biomedical Advanced…

Read More OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samplesContinue

Emergent BioSolutions joined U.S. Government’s Warp Speed Program  for COVID-19 vaccine development and manufacturing
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Emergent BioSolutions joined U.S. Government’s Warp Speed Program for COVID-19 vaccine development and manufacturing

On Jun. 1, 2020, Emergent BioSolutions announced it had been issued a task order under an existing contract…

Read More Emergent BioSolutions joined U.S. Government’s Warp Speed Program for COVID-19 vaccine development and manufacturingContinue

Phlow Corp was awarded $354 million BARDA contract to manufacture essential medicines in shortage
Biotechnology | COVID-19 | Infectious Disease | Medicine

Phlow Corp was awarded $354 million BARDA contract to manufacture essential medicines in shortage

On May 19, 2020, Phlow, a U.S.-based, public benefit drug manufacturing corporation, received federal government funding of $354…

Read More Phlow Corp was awarded $354 million BARDA contract to manufacture essential medicines in shortageContinue

Mayo Clinic received $26 million from BARDA for COVID-19 convalescent plasma expanded access program
Biotechnology | COVID-19 | Infectious Disease | Non-Profit Research | Therapeutics

Mayo Clinic received $26 million from BARDA for COVID-19 convalescent plasma expanded access program

On May 4, 2020, Mayo Clinic was awarded a $26 million contract from the Biomedical Advanced Research and…

Read More Mayo Clinic received $26 million from BARDA for COVID-19 convalescent plasma expanded access programContinue

InBios obtained BARDA funding to develop point-of-care COVID-19 test
Biotechnology | Diagnostics | Infectious Disease

InBios obtained BARDA funding to develop point-of-care COVID-19 test

On Apr. 30, 2020, InBios announced that it had been awarded a contract from the Biomedical Advanced Research…

Read More InBios obtained BARDA funding to develop point-of-care COVID-19 testContinue

Moderna announced IND Submitted to FDA for phase 2 study of mRNA vaccine (mRNA-1273) against novel Coronavirus
Biotechnology | FDA | Infectious Disease | Vaccine

Moderna announced IND Submitted to FDA for phase 2 study of mRNA vaccine (mRNA-1273) against novel Coronavirus

On Apr. 27, 2020, Moderna announced it had submitted an Investigational New Drug application to the U.S. Food…

Read More Moderna announced IND Submitted to FDA for phase 2 study of mRNA vaccine (mRNA-1273) against novel CoronavirusContinue

BARDA, Tangen Biosciences partnership pursues SARS-CoV-2 diagnostic
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medical Device

BARDA, Tangen Biosciences partnership pursues SARS-CoV-2 diagnostic

On Apr. 22, 2020, the Biomedical Advanced Research and Development Authority (BARDA) and Tangen Biosciences announced teaming up…

Read More BARDA, Tangen Biosciences partnership pursues SARS-CoV-2 diagnosticContinue

Moderna announced BARDA award for up to $483 million to accelerate development of mRNA vaccine (mRNA-1273) against novel Coronavirus
Biotechnology | Infectious Disease | Vaccine

Moderna announced BARDA award for up to $483 million to accelerate development of mRNA vaccine (mRNA-1273) against novel Coronavirus

On Apr. 16, 2020, Moderna announced an agreement for a commitment of up to $483 million from the…

Read More Moderna announced BARDA award for up to $483 million to accelerate development of mRNA vaccine (mRNA-1273) against novel CoronavirusContinue

Nanomix awarded BARDA contract for development of rapid, mobile, point-of-care assays to detect COVID-19
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Nanomix awarded BARDA contract for development of rapid, mobile, point-of-care assays to detect COVID-19

On Apr. 8, 2020, Nanomix announced that the company had been awarded $570,000 in funding from Biomedical Advanced…

Read More Nanomix awarded BARDA contract for development of rapid, mobile, point-of-care assays to detect COVID-19Continue

OraSure Technologies received BARDA contract for Rapid Oral Fluid Pan-SARS-Coronavirus in-home self-test
Biotechnology | Diagnostics | FDA | Infectious Disease

OraSure Technologies received BARDA contract for Rapid Oral Fluid Pan-SARS-Coronavirus in-home self-test

On Apr. 6, 2020, OraSure Technologies announced it had been awarded a $710,310 contract from the Biomedical Advanced…

Read More OraSure Technologies received BARDA contract for Rapid Oral Fluid Pan-SARS-Coronavirus in-home self-testContinue

Emergent BioSolutions partnered with U.S. Government to expedite development of plasma-derived therapy for COVID-19
Biotechnology | COVID-19 | Therapeutics

Emergent BioSolutions partnered with U.S. Government to expedite development of plasma-derived therapy for COVID-19

On Apr. 2, 2020, Emergent BioSolutions announced it had entered into a formal partnership with the U.S. government…

Read More Emergent BioSolutions partnered with U.S. Government to expedite development of plasma-derived therapy for COVID-19Continue

Paratek Pharma announced BARDA funding for onshoring the manufacturing supply for NUZYRA (omadacycline)
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Paratek Pharma announced BARDA funding for onshoring the manufacturing supply for NUZYRA (omadacycline)

On Apr. 1, 2020, Innovation Pharma announced BARDA had initiated funding to support the onshoring of Paratek manufacturing…

Read More Paratek Pharma announced BARDA funding for onshoring the manufacturing supply for NUZYRA (omadacycline)Continue

Cue Health awarded $13 million for rapid, portable, point-of-Care COVID-19 test by BARDA
Biotechnology | Diagnostics | Infectious Disease | Influenza | Medical Device

Cue Health awarded $13 million for rapid, portable, point-of-Care COVID-19 test by BARDA

On Mar. 31, 2020, Cue Health announced that is had been awarded up to $30 million in base…

Read More Cue Health awarded $13 million for rapid, portable, point-of-Care COVID-19 test by BARDAContinue

Philips to fulfill contract with the HHS for the delivery of 10,000 Trilogy Universal units with accelerated delivery
Biotechnology | COVID-19 | Infectious Disease | Medical Device | Therapeutics

Philips to fulfill contract with the HHS for the delivery of 10,000 Trilogy Universal units with accelerated delivery

On Mar. 31, 2020, Philips announced that it was fully committed to fulfill the contract with the U.S….

Read More Philips to fulfill contract with the HHS for the delivery of 10,000 Trilogy Universal units with accelerated deliveryContinue

Altimmune and the University of Alabama at Birmingham to collaborate on development of single-dose, intranasal COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Altimmune and the University of Alabama at Birmingham to collaborate on development of single-dose, intranasal COVID-19 vaccine

On Mar. 30, 2020, Altimmune announced that it was launching a collaboration with the University of Alabama at…

Read More Altimmune and the University of Alabama at Birmingham to collaborate on development of single-dose, intranasal COVID-19 vaccineContinue

Mesa Biotech received funding from HHS for development of a 30 minute molecular point-of-care SARS-CoV-2 test
Biotechnology | COVID-19 | Diagnostics | Influenza | Medical Device

Mesa Biotech received funding from HHS for development of a 30 minute molecular point-of-care SARS-CoV-2 test

On Mar. 19, 2020, Mesa Biotech announced it had been awarded a $561,000 contract from the U.S. Department…

Read More Mesa Biotech received funding from HHS for development of a 30 minute molecular point-of-care SARS-CoV-2 testContinue

Roche initiated phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics

Roche initiated phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

On Mar. 19, 2020, Roche announced it was working with the U.S. Food & Drug Administration (FDA) to…

Read More Roche initiated phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumoniaContinue

Sanofi joined with U.S. Dept of Health and Human Services to advance novel coronavirus vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Sanofi joined with U.S. Dept of Health and Human Services to advance novel coronavirus vaccine

On Feb. 18, 2020, Sanofi announced it had leveraged previous development work for a SARS vaccine which may…

Read More Sanofi joined with U.S. Dept of Health and Human Services to advance novel coronavirus vaccineContinue

Cue announced $30 million funding contract from BARDA and HHS
Biotechnology | Diagnostics | Influenza | Non-Profit Research

Cue announced $30 million funding contract from BARDA and HHS

On Jul. 12, 2018, Cue Health announced that is had been awarded up to $30 million in base…

Read More Cue announced $30 million funding contract from BARDA and HHSContinue

First smallpox vaccine for certain immune-compromised populations delivered under Project BioShield
Biotechnology | Infectious Disease | Non-Profit Research | U.S. Congress | Vaccine

First smallpox vaccine for certain immune-compromised populations delivered under Project BioShield

On Jul. 13, 2010, Bavarian Nordic announced that it had delivered 1 million doses of its smallpox vaccine…

Read More First smallpox vaccine for certain immune-compromised populations delivered under Project BioShieldContinue

Page navigation

Previous PagePrevious 1 2
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search